ApoB-Containing Lipoprotein Particles as Risk Factors for Coronary Artery Disease
The function of lipid transport is to facilitate the transfer of ex ogenous and endogenous triglycerides and cholesterol from their sites of absorption or formation to their sites of storage and utilization. This function is carried out by triglyceride-rich lipoproteins of intestinal and hepatic origin through a series of enzymic conversion reactions resulting in release of triglyceride fatty acids and generation of cholesterol-rich remnant lipoproteins. Under normal, steady-state conditions, the input and output of triglyceride-rich lipoproteins are balanced with little or no change in their plasma levels. However, an increased influx and/or a decreased efflux of triglyceride-rich lipoproteins from the plasma compartment have been identified as main pathophysiologic mechanisms leading to hypertriglyceridemia1. The increased formation and/or decreased removal of cholesterol-rich lipoproteins results in hypercholesterolemia which may or may not accompany typically hypertriglyceridemic states. Deranged lipid transport processes are of great clinical significance, because they are identified as one of the main factors responsible for the genesis and development of atherosclerosis2–4.
KeywordsLipoprotein Particle Plasma Triglyceride Level Atherogenic Potential Niacin Therapy Oklahoma Medical Research Foundation
Unable to display preview. Download preview PDF.
- 11.R. Tatami, H. Mabuchi, K. Ueda, R. Ueda, T. Haba, T. Kametani, S. Ito, J. Koizumi, M. Ohta, S. Miyamoto, A. Nakayama, H. Kanoya, H. Oiwake, A. Genda, and R. Takeda, Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease, Circulation 64:1174 (1981).PubMedCrossRefGoogle Scholar
- 22.P. Alaupovic, Conceptual development of the classification systems of plasma lipoproteins, Protides Biol. Fluids Proc. Colloq. 19:9(1972).Google Scholar
- 30.P. Alaupovic, C.S. Wang, W.J. McConathy, D. Weiser, and D. Downs, ipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product, Arch. Biochem. Biophys. 224:226 (1986).CrossRefGoogle Scholar
- 35.M. Tavella, P. Alaupovic, D. Blankenhorn, and H.P. Chin, Specific ffect of combined colestipol and niacin therapy on apolipoprotein B-containing particles, Arteriosclerosis 7:515a (1987).Google Scholar
- 36.V. Manninen, O. Elo, H. Frick, K. Haapa, O.P. Heinonen, P. Heinsalmi, . Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, H. Maenpaa, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, and E. A. Nikkilä, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, JAMA 260:641 (1988).PubMedCrossRefGoogle Scholar
- 37.C. Corder, M. Tavella, and P. Alaupovic, Effect of gemfibrozil on iscrete ApoB-containing lipoproteins in patients with type V hyperlipoproteinemia, Arteriosclerosis 7:515a (1987).Google Scholar
- 38.P. Alaupovic, and P.R. Blackett, The dyslipoproteinemias of diabetes ellitus, in Human Plasma Lipoproteins, J.C. Fruchart and J. Shepherd, eds., Walter de Gruyter Press, Berlin-New York, pp. 173–206 (1989).Google Scholar
- 39.A. Fontbonne, E. Eschwège, F. Cambien, J.-L. Richard, P. Ducimetière, . Thibult, J.-M. Warnet, J.-R. Claude, andG.-E. Rosselin, Hypertriglyceridiamia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris prospective study, Diabetologia 32:300 (1989).PubMedCrossRefGoogle Scholar
- 41.E. Koren, C. Corder, G. Mueller, J. Centurion, J. Fesmire, L. Hunt, nd P. Alaupovic, Coronary artery disease and triglyceride enriched lipoproteins, FASEB J. 2:A1596 (1988).Google Scholar